Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the HairCheck device was reported to accurately assess changes in hair density and diameter, suggesting its usefulness in monitoring alopecia progression and treatment response.

This study identified multiple factors affecting the severity of alopecia areata, suggesting they could inform a tool for measuring disease impact and guide treatment selection.

In this study, gene inactivation in mouse hair follicle stem cells lacking ILK impaired wound healing by reducing their progeny’s contribution to the regenerating epidermis, but did not affect hair follicle regeneration.

This research aims to address gaps in understanding alopecia areata by evaluating the real-world effectiveness and safety of baricitinib, identifying predictors of therapeutic response, and exploring the long-term impact on life quality, including sexual health. Results are not reported in the abstract.

AGD1 is important for root hair development in Arabidopsis, working with phosphoinositide signaling and the actin cytoskeleton.

In this review, the authors detailed various dermatologic adverse events associated with aromatase inhibitors in postmenopausal women and discussed strategies to potentially prevent these events, aiming to minimize interruptions in breast cancer treatment.

In this study, a mouse model with a PIK3CA gain-of-function mutation in Schwann cells revealed unique communication with neighboring cells and a glycolytic shift in peripheral nerves, and early alpelisib treatment significantly improved symptoms, though efficacy declined with delayed administration due to limited drug penetration.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.

This study reports that trichoscopy and histopathology can effectively diagnose alopecia areata incognito and differentiate it from telogen effluvium or androgenetic alopecia, aiding clinicians in better hair regrowth management.

In this case report, an African American male with signs of acne keloidalis nuchae highlights the condition's chronic nature and need for early intervention to minimize permanent scarring and its psychosocial impact.

In this study, baricitinib was well tolerated and led to clinical improvement in patients with treatment-resistant alopecia areata in a real-world clinical setting, suggesting it may be a potential treatment option.

This study found that videodermoscopy reveals distinct dermoscopic features in patients with alopecia areata incognita, aiding in biopsy decisions by identifying the appropriate sampling area and potentially avoiding unnecessary procedures.

In this study, patients with alopecia areata displayed altered scalp microbiota compared to healthy controls, and treatment with JAK kinase inhibitors largely restored these microbial changes, providing insights into the potential role of the skin microbiome in alopecia areata.

This case report describes the first observed association between alopecia areata and Kawasaki disease in a 10-year-old boy, suggesting a possible link that merits further investigation.

This study found that the enzyme A20 helps regulate EDAR-induced NF-κB signaling in mice, preventing ectodermal abnormalities like disheveled hair and assuring proper skin and appendage development.

AKR1B10 enzyme may cause keloid scars and could be a treatment target.

This study analyzed survey responses from 800 alopecia areata patients and found a possible genetic association with increased insulin-dependent diabetes mellitus in relatives but not in the patients themselves.

This scoping review found that most of the 64 alopecia areata patients treated with upadacitinib in existing reports experienced significant hair regrowth, with mild side effects, but the authors call for larger studies to confirm these outcomes.

In this study, researchers evaluated CS12192, a selective JAK3 inhibitor, in an alopecia areata mouse model and found it reversed hair growth inhibition comparably to baricitinib, with better safety and similar immune-modulating mechanisms.

This source reviews alopecia areata, highlighting its epidemiology, immune-related causes, diagnostic methods, and the shift in treatment with JAK inhibitors like baricitinib and ritlecitinib, marking the first disease-modifying options for this hair loss condition.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This article reviews alopecia areata incognita, a rare condition mostly seen in young women, and discusses its similarities and differences with telogen effluvium; however, it reports no new clinical findings.

This study found that VE-cadherin and Alk1, traditionally linked to vascular functions, also play crucial roles in maintaining nerve homeostasis in mice during hair growth cycles by modulating certain cell populations.

In this update, researchers incorporated TGA-approved Janus Kinase inhibitors into the Australian treatment guidelines for chronic, moderate to severe Alopecia areata, aiming to enhance recommended therapies by providing guidance on the use and management of these systemic medications.

This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

This review compiles epidemiological data on actinic keratoses and suggests promoting strategies like early diagnosis and photoprotection to prevent progression to skin cancer, but it reports no new clinical findings.

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

This review identified distinguishing features of adult Kawasaki Disease compared to pediatric cases, noting more favorable prognosis in adults with fewer cardiovascular complications and no fatalities, although it remains a rare and often unrecognized condition.